TORPEDO Platform
Provider 
Founded 2015
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed

C4 Therapeutics platform for discovering targeted protein degraders.
The TORPEDO Platform is C4 Therapeutics' platform for discovering and designing targeted protein degraders. It encompasses the company's degrader modalities, including monovalent degrader approaches, for eliminating disease-causing proteins.
TORPEDO supports C4 Therapeutics' pipeline of targeted protein degradation therapeutics, guiding discovery from ligand identification through preclinical development.
Adds products that compete with one of TORPEDO Platform’s direct competitors but not with TORPEDO Platform itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | TORPEDO Platform | Eclipsor | DEL-AI Discovery Engine | PROTAC Discovery Engine | |
|---|---|---|---|---|---|
| Linked Through | — | Direct competitor | Eclipsor | Eclipsor | |
| Provider | |||||
| Founded | 2015 | 2006 | 2012 | 2013 | |
| Sells To | Enterprise | Businesses | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Pre-Revenue | Recurring, Software | Recurring, Software | |
| Ownership | Venture-backed | Private | Public | Public |
Provider 
Founded 2015
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider 
Founded 2006
Sells To Businesses
Pricing Model Pre-Revenue
Ownership Private
Linked Through Eclipsor
Provider 
Founded 2012
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Linked Through Eclipsor
Provider 
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public


Nurix AI-enhanced DEL discovery engine for targeted protein degradation programs.


Arvinas' PROTAC discovery engine for developing targeted protein degrader therapeutics.
Nurix AI-enhanced DEL discovery engine for targeted protein degradation programs.

Arvinas' PROTAC discovery engine for developing targeted protein degrader therapeutics.
